EUVIMEDEUVIMED entdecken
Crossref

Teixobactin: A Resistance-Evading Antibiotic for Treating Anthrax

William S Lawrence, Jennifer E Peel, Rosan de Winter iD, Losee L Ling, Anthony G Nitti, Aaron J Peoples, Rhythm Shukla, Harold D MacGillavry, Henry S Heine, Martha E Hensel, Elbert B Whorton, Markus Weingarth iD und 2 weitere

ACS Infectious Diseases · 2025

DOI: 10.1021/acsinfecdis.4c00835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2025. Verfasst von William S Lawrence und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas 77555, United States. Hauptthemen laut MEDLINE: Anthrax, Bacillus anthracis, Anti-Bacterial Agents, Depsipeptides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthraxBacillus anthracisAnti-Bacterial AgentsDepsipeptidesDrug Resistance, BacterialAnimalsRabbitsDisease Models, AnimalRespiratory Tract Infections

Stichwörter der Autor:innen

anthraxantimicrobial resistance crisisteixobactin

Substanzen

Anti-Bacterial AgentsteixobactinDepsipeptides

Autor:innen und Institutionen

  • Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
  • NMR Spectroscopy, Bijvoet Centre for Biomolecular Research, Department of Chemistry, Faculty of Science, Utrecht University, Utrecht 3584 CS, Netherlands.
  • NovoBiotic Pharmaceuticals, LLC, Cambridge, Massachusetts 02138, United States.
  • Cell Biology, Neurobiology and Biophysics, Department of Biology, Faculty of Science, Utrecht University, Utrecht 3584 CS, Netherlands.
  • Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida 32827, United States.
  • Department of Comparative Medicine and Research, University of Texas MD Anderson, Bastrop, Texas 78602, United States.

ORCID-Profile: Rosan de Winter, Markus Weingarth, Dallas E Hughes

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • U.S. Department of Defense
  • H2020 European Research Council

Zitieren

APA

Lawrence, W. S., Peel, J. E., de Winter, R., Ling, L. L., Nitti, A. G., Peoples, A. J., Shukla, R., MacGillavry, H. D., Heine, H. S., Hensel, M. E., Whorton, E. B., Weingarth, M., Lewis, K., & Hughes, D. E. (2025). Teixobactin: A Resistance-Evading Antibiotic for Treating Anthrax. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00835

Vancouver

Lawrence WS, Peel JE, de Winter R, Ling LL, Nitti AG, Peoples AJ, et al. Teixobactin: A Resistance-Evading Antibiotic for Treating Anthrax. ACS Infectious Diseases. 2025. doi:10.1021/acsinfecdis.4c00835

BibTeX
@article{Lawrence2025,
  author = {Lawrence, William S and Peel, Jennifer E and de Winter, Rosan and Ling, Losee L and Nitti, Anthony G and Peoples, Aaron J and Shukla, Rhythm and MacGillavry, Harold D and Heine, Henry S and Hensel, Martha E and Whorton, Elbert B and Weingarth, Markus and Lewis, Kim and Hughes, Dallas E},
  title = {Teixobactin: A Resistance-Evading Antibiotic for Treating Anthrax},
  journal = {ACS Infectious Diseases},
  year = {2025},
  doi = {10.1021/acsinfecdis.4c00835}
}
Kostenlos starten →